DUOGLOBE: One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease

BACKGROUND: Levodopa‐carbidopa intestinal gel (LCIG) is an established treatment for improving motor and some non‐motor symptoms (NMS) in patients with advanced Parkinson's disease (PD). Prospective long‐term data in routine clinical practice are limited. OBJECTIVE: Assess LCIG effectiveness an...

Descripción completa

Detalles Bibliográficos
Autores principales: Standaert, David G., Aldred, Jason, Anca‐Herschkovitsch, Marieta, Bourgeois, Paul, Cubo, Esther, Davis, Thomas L., Iansek, Robert, Kovács, Norbert, Pontieri, Francesco E., Siddiqui, Mustafa S., Simu, Mihaela, Bergmann, Lars, Kukreja, Pavnit, Robieson, Weining Z., Chaudhuri, K. Ray
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485588/
https://www.ncbi.nlm.nih.gov/pubmed/34631942
http://dx.doi.org/10.1002/mdc3.13239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485588/
https://www.ncbi.nlm.nih.gov/pubmed/34631942
http://dx.doi.org/10.1002/mdc3.13239

Ejemplares similares